FY2025 Earnings Estimate for Cidara Therapeutics, Inc. (NASDAQ:CDTX) Issued By HC Wainwright

Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Cidara Therapeutics in a note issued to investors on Thursday, April 25th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will earn $12.63 per share for the year, up from their previous forecast of $12.60. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($13.00) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ FY2026 earnings at $18.85 EPS and FY2027 earnings at $40.32 EPS.

CDTX has been the subject of several other research reports. Needham & Company LLC boosted their price objective on Cidara Therapeutics from $3.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Cidara Therapeutics in a research report on Tuesday. Finally, WBB Securities restated a “strong-buy” rating and issued a $40.00 target price on shares of Cidara Therapeutics in a report on Thursday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cidara Therapeutics presently has a consensus rating of “Buy” and an average price target of $71.25.

Cidara Therapeutics Trading Down 1.8 %

Shares of NASDAQ CDTX traded down $0.24 during mid-day trading on Friday, hitting $12.76. The company had a trading volume of 74,702 shares, compared to its average volume of 48,337. Cidara Therapeutics has a 12 month low of $10.00 and a 12 month high of $29.60. The firm’s 50 day simple moving average is $15.37 and its two-hundred day simple moving average is $15.33.

Institutional Investors Weigh In On Cidara Therapeutics

A number of hedge funds have recently modified their holdings of the company. Pale Fire Capital SE acquired a new position in shares of Cidara Therapeutics during the 3rd quarter worth $51,000. Flagship Harbor Advisors LLC purchased a new stake in Cidara Therapeutics in the 3rd quarter worth about $28,000. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in shares of Cidara Therapeutics by 25.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 15,912 shares during the last quarter. Hedge funds and other institutional investors own 35.82% of the company’s stock.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.